Janus kinase inhibitors therapy in idiopathic inflammatory myopathies: a case series

Key Points

• Patients treated with JAK inhibitors showed clinical improvement, particularly in interstitial lung disease.
• JAKi treatment demonstrated a notable steroid-sparing effect, enhancing patient management options.
• Observational analysis of refractory idiopathic inflammatory myopathies used JAK inhibitors to assess effectiveness and safety.
• Future studies are necessary to confirm the results and expand understanding of JAK inhibitors' role in therapy.

Abstract